Stay updated on Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.

Latest updates to the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov page now displays the study record for the phase II trial of DCVax-L and nivolumab for recurrent glioblastoma, including its withdrawn status and detailed study information, rather than a 403 error page.SummaryDifference77%

- Check15 days agoChange DetectedThe site footer revision label changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedAn NIH sitewide notice appears above the 403 error page, linking to transition updates and stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.7.1 instead of v3.7.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating the study record is temporarily inaccessible.SummaryDifference23%

Stay in the know with updates to Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.